Form 4: Tarsus Pharmaceuticals Director Morrison Reports Stock Transactions
SEC Form 4 Filing
Director Scott W. Morrison of Tarsus Pharmaceuticals reports the acquisition and disposal of common stock and restricted stock units.
Summary
- On September 15, 2024, Scott W. Morrison, a director of Tarsus Pharmaceuticals, engaged in transactions involving the company's stock.
- Morrison acquired 1,333 shares of common stock through the vesting of Restricted Stock Units (RSUs).
- He also disposed of 1,333 shares.
- Following these transactions, Morrison directly owns 6,016 shares of common stock and 1,334 derivative securities.
- The RSUs vest in three equal annual installments on September 15th of 2023, 2024, and 2025.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company directors.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the overall impact is likely minimal.
Key Dates
| Date | Description |
|---|---|
| 09/15/2023 | First vesting date of Restricted Stock Units. |
| 09/15/2024 | Date of stock transactions and second vesting date of Restricted Stock Units. |
| 09/15/2025 | Final vesting date of Restricted Stock Units. |
| 09/17/2024 | Date of signature by Attorney-in-Fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.